Comparison
Argireline vs. Dulaglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Metabolic
CAS no.
616204-22-9
923950-08-7
Molecular weight
888.99 g/mol
59670 g/mol
Half-life
no data
110 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcMechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
5
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
2